Predicting response to rivastigmine in dementia with Lewy Bodies

Wesnes, K. A.; McKeith, IG; Ferrara, Roberto; Emre, Murat; Spiegel, René

doi:10.1016/s0924-977x(02)80607-1

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Often, patients report seeing people and animals that are real but make no noise; emotional reactions vary from intense fear to indifference or even amusement [31]. Visual hallucinations are associated with greater deficits in cortical Acetylcholine [35] and predict greater response to cholinesterase inhibitors [36] . Although the hallucinations are similar in quality to those of Parkinson's Disease with dementia, they occur more frequently in DLB [25].…”

Section: Dementia With Lewy Bodies (Dlb)mentioning

confidence: 99%

Differentiating the Dementias. Revisiting Synucleinopathies and Tauopathies

Hickey

Chisholm²,

Passmore³

et al. 2008

CAR

View full text Add to dashboard Cite

Dementia is a common, chronic and progressive illness. Many different types of dementia exist. It is important to have knowledge of the various dementia presentations so that the clinician can differentiate one type from another. Past and current approaches of classifying dementias are reviewed in this paper. The past cortical/subcortical scheme is reviewed as well as the current synucleinopathy/tauopathy scheme. This paper focuses on the most common synucleinopathies and tauopathies including Alzheimer's Dementia, Dementia with Lewy Bodies, Parkinson's Disease, Frontotemporal Dementia, Progressive Supranuclear Palsy, Multiple System Atrophy and Corticobasal Ganglionic Degeneration. We systematically approach each dementia and review cognitive, psychiatry and neurological features of each. We also compare and contrast each dementia and the synucleinopathies and taupoathies alike. Our goal is to provide the clinician with sufficient knowledge to competently and confidently diagnose a patient who presents with progressive cognitive decline and deterioration in functioning.

show abstract

Section: Dementia With Lewy Bodies (Dlb)mentioning

confidence: 99%

Differentiating the Dementias. Revisiting Synucleinopathies and Tauopathies

Hickey

Chisholm²,

Passmore³

et al. 2008

CAR

View full text Add to dashboard Cite

show abstract

“…Later analyses have suggested that the drug improved cognitive test scores that involved attention. 31 34 A small open study of rivastigmine in patients with subcortical vascular dementia showed behavior and executive functions were significantly improved as compared with baseline. 35 A large multicenter placebo-controlled trial in patients with vascular dementia is currently underway.…”

Section: Therapy For Other Dementiasmentioning

confidence: 99%

Update on Rivastigmine

Farlow

2003

The Neurologist

View full text Add to dashboard Cite

show abstract

Dementia with Lewy bodies

McKeith¹,

Mintzer²,

Aarsland³

et al. 2004

The Lancet Neurology

623

412

View full text Add to dashboard Cite

Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein alpha-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.

show abstract

Predicting response to rivastigmine in dementia with Lewy Bodies

Cited by 3 publications

References 0 publications

Differentiating the Dementias. Revisiting Synucleinopathies and Tauopathies

Differentiating the Dementias. Revisiting Synucleinopathies and Tauopathies

Update on Rivastigmine

Dementia with Lewy bodies

Contact Info

Product

Resources

About